作者: Bos, Hendericus ; Leppäaho, Eemeli ; Glatzer, Timor ; Koehler, Matthias ; Peak, Ajandek ; Ringemann, Christian ; Lustenberger, Patrick ; Babion, Nils ; Klopfenstein, Yannick ; Andorrà, Magí ; Herrero, Pau

Background: Despite abundant evidence demonstrating the benefits of continuous glucose monitoring (CGM) in diabetes management, a significant proportion of people using this technology still struggle to achieve glycemic targets. To address this challenge, we propose the Accu-Chek® SmartGuide Predict app, an innovative CGM digital companion that incorporates a suite of advanced glucose predictive functionalities aiming to inform users earlier about acute glycemic situations. Methods: The app’s functionalities, powered by three machine learning models, include a two-hour glucose forecast, a 30-minute low glucose detection, and a nighttime low glucose prediction for bedtime interventions. Evaluation of the models’ performance included three data sets, comprising subjects with T1D on MDI (n = 21), subjects with type 2 diabetes (T2D) on MDI (n = 59), and subjects with T1D on insulin pump therapy (n = 226). Results: On an aggregated data set, the two-hour glucose prediction model, at a forecasting horizon of 30, 45, 60, and 120 minutes, achieved a percentage of data points in zones A and B of Consensus Error Grid of: 99.8%, 99.3%, 98.7%, and 96.3%, respectively. The 30-minute low glucose prediction model achieved an accuracy, sensitivity, specificity, mean lead time, and area under the receiver operating characteristic curve (ROC AUC) of: 98.9%, 95.2%, 98.9%, 16.2 minutes, and 0.958, respectively. The nighttime low glucose prediction model achieved an accuracy, sensitivity, specificity, and ROC AUC of: 86.5%, 55.3%, 91.6%, and 0.859, respectively. Conclusions: The consistency of the performance of the three predictive models when evaluated on different cohorts of subjects with T1D and T2D on different insulin therapies, including real-world data, offers reassurance for real-world efficacy.

2024-06-26·SPE Europe Energy Conference and Exhibition

Deployment of an Artificial Intelligence-Based Well Integrity Monitoring Solution

作者: Dillen, M. ; Koziol, T. ; Nitsche, M. ; Sanchez, F. P. A. ; Kimari, T. ; Eita, M. ; Tomina, M. ; Zhukova, K. ; Schemmer, M. ; Aditama, P.

AbstractThis paper provides comprehensive insights into deploying and operationalizing an Artificial Intelligence (AI)-based well integrity monitoring solution. The paper's central objective is to present the successful implementation of the advanced monitoring solution, focusing on the insights collected from employing Machine Learning Operations (MLOps) principles within the oil and gas industry. Following a successful Proof of Concept (PoC) phase, the project progressed to developing the Minimum Viable Product (MVP), involving the deployment of selected AI models through stages consisting of live data connection, pre-processing, inferencing, post-processing, suppression rules, and email notification, complemented by the development of a user interface to facilitate visualization and validation of notifications, with user feedback stored in a database for continuous model enhancement. Drawing from the conclusions derived from the project, several key insights are provided. Firstly, the strategic architecture of the MVP emerges as a pivotal factor for transitioning from the PoC phase to the final product. The MVP must be carefully crafted to facilitate rapid learning through iterative user feedback while ensuring technical feasibility and economic viability. Secondly, introducing the "AI factory" concept is identified as a fundamental enabler of efficiency in both model development and deployment process, particularly relevant as project teams expand. Thirdly, incorporating MLOps principles and best practices provides invaluable guidance in constructing a scalable AI solution without pre-existing architecture. Fourthly, integrating the "Human-In-The-Loop" concept underlines the importance of continuous feedback in refining and maintaining the continuous operation of AI solutions. Fifthly, central to user adoption is the emphasis on user experience, with specialized suppression rules and an intuitive user interface pivotal in facilitating user validation of detections. Sixthly, explainable AI methodologies play a crucial role in fostering trust in the tool's performance by explaining the rationale behind AI model decisions. Seventhly, the deployed tool performs robustly detecting annulus leakage incidents with high accuracy and minimal false alarms, significantly reducing engineers’ response time. Eighthly, challenges encountered during the scaling process across different assets, such as data availability and quality variations, were addressed through tailored data pre-processing methods and feature engineering techniques. Ninthly, leveraging expertise in real-time data analytics, the tool was extended to address additional use cases, including automatic leak rate test analysis and liquid loading detection and prediction. Finally, counterfactual explanations for LSTM (Long Short-Term Memory) autoencoder models are introduced. It represents a significant technical advancement and is qualitatively evaluated for its impact on user experience. This paper contributes valuable insights into deploying and operationalizing AI-based well integrity monitoring solutions, with practical implications for industry practitioners.

2023-01-01·84th EAGE Annual Conference & Exhibition

Exploration Advisory Tool: AI and NLP in the Geosciences

作者: Entrup, B. ; Dillen, M.

127

项与 IBM Deutschland GmbH 相关的新闻（医药）

2023-01-03

·Business Wire

Worldwide Ophthalmology PACS Industry to 2030 - Featuring Agfa-Gevaert, Sonomed Escalon, Carl Zeiss Meditec and EyePACS Among Others - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Ophthalmology PACS Market, by Type, by Delivery Model, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022-2030" report has been added to ResearchAndMarkets.com's offering. Picture Archiving and Communication System (PACS) is a medical imaging technology used in healthcare organizations. A PACS has diverse types of data and databases, which are usually stored in different formats. They contain demographic, images, and Digital Imaging and Communications in Medicine (DICOM) data. Image data may be treated as objects while patient data may be stored as script. Having access to a patient's most recent clinical pictures, medical reports, and history digitally helps speed up, enhance care and improve therapy. Digital access can advance patient safety and save healthcare facility and the patient's time and money. PACS has four machineries which include hardware imaging machines, a secure network for the transmission and exchange of patient pictures, mobile device for viewing, processing, and interpreting images, and electronic records for storage and retrieving images and related reports. Market players are involved in advancing technologies for ophthalmic care, which is further expected to drive the growth of the global ophthalmology PACS market over the forecast period. For instance, on April 6, 2022, Carl Zeiss Meditec AG, a medical technology company, displayed medical viewpoints from global experts whose experiences support the importance of integrating devices, data, and software applications. New integrated ophthalmic workflows allow to create a digital environment where connectivity, automation, artificial intelligence, and safe management of data are redesigned for patient care. Updated guidelines by regulatory bodies for securing Picture Archiving and Communication System is also expected to drive the growth of the global ophthalmology PACS market over the forecast period. For instance, in September 2019, the National Cybersecurity Center of Excellence (NCCoE) had updated guidelines for securing PACS such as improve flexibility in the network infrastructure with controlling a capability of a person trying to harm the computers device or systems of the healthcare delivery organization and controlling the unauthorized movement of files within the healthcare delivery organization by official system operators as well as it analyzes the actions and detect malware throughout the ecosystem and also NCCoE protects sensitive data. Increasing security for protecting PACS data is expected to boost the global ophthalmology PACS market growth. Key features of the study: This report provides an in-depth analysis of the global ophthalmology PACS market, market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players It profiles leading players in the global ophthalmology PACS market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans Insights from this report would allow marketers and management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics The global ophthalmology PACS market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ophthalmology PACS market. Market Segmentation: Global Ophthalmology PACS Market, By Type: Integrated PACS Standalone PACS Global Ophthalmology PACS Market, By Delivery Model: Cloud-Based Model On-Premise Model Global Ophthalmology PACS Market, By End User: Hospitals Speciality Clinics Global Ophthalmology PACS Market, By Region: North America Latin America Europe Asia Pacific Middle East Africa Company Profiles Topcon Corporation Agfa-Gevaert N.V. Sonomed Escalon Carl Zeiss Meditec AG EyePACS VersaSuite Heidelberg Engineering GmbH ScImage, Inc. IBM Corporation Visbion Limited For more information about this report visit https://www.researchandmarkets.com/r/2mt0g9

2023-01-03

·Business Wire

Worldwide Specialty PACS Industry to 2029 - Featuring IBM, McKesson, Agfa Healthcare and Sectra Among Others - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Specialty PACS Market Analysis by Type, by Component, by Deployment Model, End user and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. The specialty PACS market size is estimated to be USD 2.9 billion in 2021 and is expected to witness a CAGR of 8.62% during the forecast period 2022-2029. The growing geriatric population and consequent increase in the incidence of various diseases, benefits associated with specialty PACS, government efforts boost the acceptance of healthcare IT solutions, rising investments in medical imaging, increased adoption of medical imaging IT solutions, and expanding use of imaging equipment are some of the key drivers for the market growth. However, budgeting restrictions are expected to restrain the market growth. Companies Mentioned IBM Corporation (Merge Healthcare Incorporated) (US) McKesson Corporation (US) Agfa Healthcare (Belgium) Carestream Health (a part of Onex Corporation) (Canada) Philips Healthcare (Netherlands) Sectra AB (Sweden) Siemens Healthineers (Germany) Novarad (US) INFINITT North America (US) Intelerad Medical Systems (Canada) Topcon Corporation (Japan) Sonomed Escalon (US) Canon USA Inc. (US) (a subsidiary of Canon Inc.) Visbion (UK) EyePACS LLC (US) Market Segmentation: By Type (Revenue, USD Billion) Radiology PACS Ophthalmology PACS Endoscopy PACS Women's Health PACS Oncology PACS Orthopaedics PACS Pathology PACS Dermatology PACS Neurology PACS Others By Component (Revenue, USD Billion) Software Services Hardware By Deployment Model (Revenue, USD Billion) Cloud-based On-premise By End user (Revenue, USD Billion) Ambulatory Surgery Centres Diagnostic Imaging Centres Hospitals Others By Region (Revenue, USD Billion) North America U.S Canada Europe Germany France UK Spain Italy Rest of Europe Asia Pacific China Japan India Australia South Korea Rest of APAC Latin America Brazil Mexico Argentina Rest of LATAM Middle East & Africa South Africa GCC Rest of MEA For more information about this report visit https://www.researchandmarkets.com/r/a1cimr

2023-01-02

·动脉网

投资项目超过250个，拥有国企背景的以色列数字医疗公司Infinity Medical将如何与中国合作？

作为医疗市场最受关注的领域之一，数字医疗拥有强劲的全球增长前景。到2024年，数字医疗全球市场规模超过2000亿美元。作为享誉全球的创新之国，以色列的数字医疗投资率是全球平均水平的4倍，其投资额从2020年的6.5亿美元上升至2022年的11亿美元，并在2022年第二季度创下风险投资的历史新高。目前，以色列拥有550多家活跃于数字医疗领域的初创企业，其中一半处于后期产品阶段。以色列本国的风险投资公司是它们最主要的支持来源，同时外国风险投资公司和CVC对于以色列数字医疗的兴趣逐步上升。在全球数字医疗领域最活跃的十位投资者中，有六位都投资过以色列公司，包括Tiger Global Management和General Catalyst等巨头。除此之外，中国投资者也在重金押注以色列的企业。2014-2019年以色列数字医疗投资增长图源：Invest In Israel2020年12月，海峡创新董事长曹阳、英飞尼迪集团董事长Amir Ga-lor（高哲铭）等出席了以色列数字医疗公司Infinity Medical (I.I.M Infinity INNONATION Medical)的线上签约仪式。该公司由海峡创新与英飞尼迪集团共同创立，致力于投资数字医学领域的公司。英飞尼迪是中国国企华发集团旗下的股权投资平台，在人民币基金领域拥有领先地位，致力于建立并深化以色列知识技术与中国市场之间的互利关系，目前管理资金超过百亿，管理企业超百家企业。海峡创新于2012年在深交所创业板上市，主要业务是智慧医疗和智慧城市。2019年，海峡创新实际控制人变更为平潭综合实验区国有资产局，由此转型为国资控股企业。2021年1月5日，Infinity Medical以色列证券交易所公开上市。时至今日，Infinity Medical已完成250多项投资，拥有15亿美元投资组合，平均内部收益率超过25%。本文主体关系图动脉网制图那么，这家由国企下场组建的以色列公司究竟有何优势？又能够为中国带来什么呢？以色列：“低风险高回报”的投资环境以色列完善的数字生态系统为各类市场参与者提供了发展数字医疗的沃土。首先，以色列98%的人口享有全面的健康保险。其次，以色列的四家HMO（健康维护组织）及其附属医院在过去二十年中一直使用相同的电子病历平台。因此，这个人口800万的国家在过去二十多年得以积累下大量关于适应症和患者治疗的数据。与此同时，在过去二十年中，许多医疗器械和制药行业的全球领导者都通过收购以色列老牌企业或与之建立合作关系、开设新的创新中心，在以色列开展业务并扩大其规模。这样不断发展的环境还造就了生命科学领域的高技能人才。根据2019年全球技能指数（Global Skills Index）报告，以色列人的数据科学技能在全球排名第一。该地区人工智能和数据分析领域人才储备同样充分。另外，以色列政府对数字医疗和健康数据的发展提供鼎力支持。2018年，以色列政府设立了一项国家数字健康计划，预计在5年内投入2.75亿美元。该数字化项目专注于二次使用脱敏临床数据，使研究人员借助人工智能系统解析数据，以寻找出最有效的疗法或开发新的疗法。能够获得高质量的创新交易流程和高效、具有成本效益的研发和临床试验，对于来自世界各地的市场参与者而言，以色列提供了一个风险相对较低但回报较高的环境。因此，该地区吸引了许多服务供应商、数字医疗基金，拥有成熟的孵化器，帮助初创企业开展研发和商业化活动。以“中国通”为核心的多元化团队与许多同行一样，Infinity Medical由医学、技术、投资和资本领域的知名专家组成。而从董事到投资委员会，Infinity Medical团队成员的个人经历似乎更具多元化色彩。投资委员会主席Amir Gal-Or（高铭哲）是英飞尼迪集团的创始管理合伙人，从事风险投资行业近30年。同时，他还是中国以色列商会的名誉会长，以及以色列空军的战斗飞行员。Gal-Or于2002年开始与中国合作开展业务，于2010年与家人在北京定居，同年创办了中国第一家知识产权银行，与具有全球战略的中国企业家和公司合作。“中国的独特之处在于其不断流动的资本和人力资源。唯一的问题是如何形成正确的商业模式和结构，以从巨大的能量流中汲取灵感，”Gal-Or 说。当被问及多年来孵化科技创业公司的经历，Gal-Or表示，近年来全球范围内的投融资热度一直呈下降趋势，同时人们期望孵化器将资金、建议、服务和其他资源投入初创企业，这就加剧了股权所有者的损失。“一切都是为了获取资源，”Gal-Or说。“建立一个好的孵化器的唯一方法是拥有非常高效的流量——让所有资源流通起来。”Amir Gal-Or 图源：Infinity Medical官网Infinity Medical的创始人Yuval Bloch博士是一名职业儿科医生，于本古里安大学获得医学博士，参与过以色列、中国和非洲的卫生服务和医院规划工作。目前Yuval Bloch在公共和私人医疗保健系统中担任各种管理职位，并创立了医疗咨询公司Ichilov International和AOI Medical Consulting。虽然已经从一名医生转变为风险投资基金管理者，但现在Yuval Bloc每周仍会用五个小时在一个社区诊所照顾孩子，确保不与临床工作完全脱节。Infinity Medical的董事之一Rivka Carmi教授则是国际知名的儿科医生和遗传学家，发表过150多篇遗传学论文。除了学者，她还是以色列大学的第一位女校长，任职期间带领该学校获得了以色列学术界历史上最大的财政捐助。在整个职业生涯中，Carmi致力于为职场和学术界的女性争取权利。她曾与政府合作，推动帮助女性成为生物技术领导者的计划，并在以色列大学推行了让女性在学术界领导职位获得平等机会的政策。2015年，Carmi教授被选为BBC最具影响力的100位女性之一。投资组合覆盖数字医疗最火热细分领域Infinity Medical利用其在创新、全球创业和投资战略方面的专业知识，为那些已推出先进产品的初创数字医疗公司增值。这些独角兽企业的旗舰产品或技术则反映了Infinity Medical长远的投资眼光。2021年，世界上首个社区驱动的基因组数据平台Genoox通过Infinity Medical等投资者筹得了800万美元资金。Genoox拥有世界上最大的综合遗传和症状数据库。工作人员可利用基于云的网络，访问和分析由数百家公司、医疗组织和患者组成的全球用户社区提供的信息，将其与全球数据进行比较。有赖于该平台，医院、健康科技公司、制药公司以及开发中心可以根据每位患者的特定基因结构提高检测的准确性。近年来，诊断一直是以色列数字医疗市场最热门的细分领域。据Start-up Nation Central统计，2021年，诊断领域的投融资额占整个数字医疗市场的32%，连续两年超过3亿美元。除了诊断，Infinity Medical当前的投资组合还涉及治疗和护理（biobeat、Theranica、Nanomedic）、决策支持（Polaris Quantum Biotech）、临床工作流程（Cynerio）领域的产品，覆盖以色列数字医疗市场在过去几年投融资最活跃的几个细分领域。Infinity Medical投资组合动脉网制图延续英飞尼迪8倍回报跨境投资模式，对外投资总额同比增长11.4%Infinity Medical采用的是英飞尼迪集团坚持了近30年的投资模式。英飞尼迪集团成立于1993年，是专注于中国市场的跨境投资集团，目前已完成上百次交易并成功退出30多笔。其核心投资者包括以色列IDB集团、美国Access Industries、中国国家开发银行和苏州元禾控股有限公司等。英飞尼迪专门投资那些寻求中国战略合作伙伴的以色列企业，并凭借其商业和政府关系帮助它们以较低的成本在中国建立生产基地。中国企业也可通过英飞尼迪的商业网络接触到最先进的产品和技术，以获得长期资本增值。此外，英飞尼迪集团已在中国多个城市设立了基金，结合当地产业优势，对境内外优质成长性企业的未上市股权进行投资，推进当地企业升级。其跨境业务则致力于帮助中国企业走出去，通过更符合国际标准的交易架构和激励方案，帮助中国企业减少政治障碍，获得更高的投资回报。我们以英飞尼迪投资孵化的一个典型案例来进行说明。2004年，位于耶路撒冷的半导体公司Shellcase的股东（包括大型全球企业集团）出现亏损，公司危在旦夕。就在这时，Gal-Or和英飞尼迪集团的其他合伙人决定以1900万美元的融资介入拯救Shellcase。此举还获得了之后的苏州工业园区的支持。作为英飞尼迪在中国的商业模式的标准组成部分，此次融资项目还包括一项重组计划——将Shellcase的制造和营销转移到中国，并将公司名更改为EIPAT，通过出售其技术许可和继续开展联合研发项目来盈利。重组八个月后，Shellcase（现为EIPAT）的IP以3300万美元的价格出售给了Tessera Technologies，但它保留了中国市场的许可。凭借这张牌照，WLCSP于2005年6月在中国成立，该公司到之后实现盈利仅用了12个月。如今，WLCSP已成为晶圆级封装领域的全球领导者，并于2014年2月在上海证券交易所上市。Shellcase/WLCSP是以色列与中国IP合作的成功范例。两家公司的重组实现了双重退出带来的利益：当Shellcase出售给Tessera时，英飞尼迪从以色列实体退出，后又在WLCSP上市时，从中国实体退出，最终共获得8倍的投资回报。英飞尼迪集团双重退出策略图源：Infinity Medical这种“中国本土商业企业+国际投资（美元或人民币）+先进技术”的投资方式给各方带来更多退出、上市或并购机会。Infinity Medical也沿用集团这一模式，关注活跃于数字医疗领域的新兴公司，并引领其走向全球，最终实现每一个参与者的利润增长——正如Gal-Or所说，要“让所有资源流通起来”。据Infinity Medical财报显示，该公司在2021年全年获得了12.7万美元的融资收入。2022年上半年，Infinity Medical开展业务的活跃度显著上升。截至2022年6月30日，Infinity Medical支出总额同比增长约为62.4%，其中以融资费用占比最高（约48.2%），增长最为显著（约250%）；其经营活动现金流量流出较上一年同期增加46万美元，同比增长108%；投资活动现金流量流出较上一年同期增加45万美元，同比增长150%。Infinity Medical 2022年中期投资报告动脉网制图Infinity Medical 2022年上半年对外投资总额同比增长11.4%，增加75万美元，全部来自于对Nanomedic的贷款性投资。以色列顶级数字医疗资源为国企赋能根据Infinity INNONATION Medical IIM线上签约仪式的会议实录，海峡创新与英飞尼迪集团将利用特拉维夫医疗中心(Ichilov)的研发能力，以及IBM Israel的支持，将以色列数字医疗技术引入中国，共同领导Infinity INNONATION Medical IIM投资组合在中国的落地和发展。Infinity Medical投资委员会委员Uri Hayik是IBM Israel的首席技术官，负责IBM Alpha-Zone加速计划的活动。作为IBM在数字医疗领域开展的活动之一，IBM Alpha-Zone将为参与公司提供咨询和技术指导，为其进入市场做好充分准备。特拉维夫医疗中心是以色列第二大公立医院，拥有世界上最大的急诊室，也是以色列数字化技术最为先进的医疗中心。在该医院，早期前列腺癌成功率90%、转移性乳腺癌成功率90%。其创新公司Ichilov Tech致力于为医院与初创企业创建合作机会，在创意验证、孵化、临床试验、知识产权许阶段提供创新方案，并与Infinity Medical保持合作关系。此前，海峡创新还与特拉维夫医疗中心的商业化运营公司（ICHILOV INNONATION LTD）、北京以创中合科技有限公司、英飞尼迪集团有限公司（Infinity）共同成立以色列特拉维夫医疗中心国际有限公司，在海峡创新互联网医院的基础之上，构建以以色列医疗体系为核心的国际医疗合作平台。特拉维夫医疗中心国际有限公司股权架构图源：海峡创新其以色列团队包括Yuval Bloch在内的成员，分别在以色列卫生部、医疗集团、风险投资集团担任核心职位。成立后，该公司将拥有Ichilov国际医疗咨询服务在大中华区的独家业务开拓权，为中国提供以色列医疗技术、医院规划设计、JCI国际认证辅导、医疗管理经验、远程医疗服务等资源。通过这种国际合作模式，海峡创新将获得以色列项目资源、合作平台资源，加强其智慧医疗业务的国内市场壁垒。2021年1月，中国国药集团中国医药投资有限公司也与Infinity Medical签署合作协议。根据协议，该公司将通过Infinity Medical在特拉维夫开展合资企业医疗业务，并寻找以色列投资机会。同时Infinity Medical还与国药集团国健资本签署了合资协议，以在中国推广和分销Infinity Medical投资组合公司的数字医疗产品。Yuval Bloch博士表示：“该协议是以色列与中国在数字医疗领域架起的一座桥梁，它是以色列和中国公司进一步成功开展业务合作的基础，也是两国共有的经济增长的引擎。”*封面图片来源：123rf左右滑动查看更多近期推荐声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。动脉网，未来医疗服务平台

并购引进/卖出

100 项与 IBM Deutschland GmbH 相关的药物交易

登录后查看更多信息

100 项与 IBM Deutschland GmbH 相关的转化医学

登录后查看更多信息